1. Generics Bulletin
  2. >>Business

Accord Unveils New Ventures After A Year Of Change

Major Moves Seen As EMENA Chief Paul Tredwell Sets Out Vision For The Company

 
• By Dave Wallace

A year after taking up the lead for Accord in the EMENA region, Paul Tredwell talks to Generics Bulletin in detail about the changes that he has already overseen in the role, as well as unveiling a number of new business initiatives, acquisitions and appointments that form part of his long-term growth strategy.

Paul Tredwell
Accord’s EMENA chief Paul Tredwell sets out his vision for the company • Source: Accord Healthcare

Accord Healthcare can be proud of its record of industry recognition, especially following an impressive quadruple win at this year’s Global Generics & Biosimilars Awards 2022 that included the firm being crowned as global company of the year (see sidebar).

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Generics Bulletin for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Strategy

More from Business

What’s Next? Five Things To Look Out For In May

 
• By Dean Rudge

Generics Bulletin previews the most noteworthy and anticipated events for May 2025.

Sandoz And Henlius Join Forces With $300m Ipilimumab Deal

 
• By Dave Wallace

Sandoz has struck a deal worth up to $301m with Henlius giving it rights to a proposed ipilimumab biosimilar to Yervoy in countries across the world.

Speranza Starts Generics Offshoot In Response To Wider US Pharma Manufacturing Drive

 
• By Adam Zamecnik

Reflecting increased regulatory pressure and a wider drive towards the reshoring of pharmaceutical manufacturing to the US, Speranza has launched a new generics business called Lotus Therapeutics.